Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis

Reuters2026/08/10 19:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immix highlighted NXC-201, a BCMA-targeted CAR-T, as its lead program for relapsed or refractory AL amyloidosis.
NEXICART-2 U.S. open-label single-arm phase 1/2 trial enrollment completed at 45 patients; primary efficacy measure is complete hematologic response.
Presentation cited a 95% complete response rate for NXC-201, versus 0-10% complete response rates reported for investigator’s-choice regimens.
Company outlined a planned BLA submission following 1-year follow-up for all 45 patients; next trial update targeted for late September 2026.
Commercial launch plan targets end of 2027; pricing reference cited USD 588,000 for 2026 Carvykti BCMA CAR-T.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis

You may also like

Crypto prices